Kornimate/medical-research-clean huggingface dataset:
to compare the efficacy of endoscopic ultrasound assisted endoscopic glue injection and conventional endoscopic injection therapy for prevention of gastric variceal rebleed

Conditions: Bleeding Gastric Varices

Summary: consecutive patients who meet the eligibility criteria will be enrolled into the study. all patients with gastric varices with no history of gastric variceal bleed (group c) will undergo endoscopic ultrasound and upper gastrointestinal endoscopy at baseline, at the end of first year and at the end of study. the patients who presented to institute of liver and biliary sciences with gastric variceal bleed or develop gastric variceal bleed during hospital stay will be randomized into group -a (conventional upper gastrointestinal endoscopy + glue) and group-b (endoscopic ultrasound followed by upper gastrointestinal endoscopy+glue) therapy for gastric varices. total 90 patients will be enrolled and randomized into group a and group b after resuscitation and urgent upper gastrointestinal endoscopy with standard therapy for bleeding gastric varices to achieve hemostasis.


Eligibility criteria:
inclusion criteria: * a clinical, radiological or histologic diagnosis of cirrhosis * upper gastrointestinal endoscopy showing gastric varices * informed consent to participate in the study exclusion criteria: * previous endotherapy (endoscopic variceal ligation/esophageal variceal sclerotherapy/endoscopic variceal obliteration) for gastric variceal haemorrhage * diagnosed case of hepatopulmonary syndrome. * non -cirrhotic portal hypertension/extra hepatic portal venous obstruction * transhepatic intrajugular portosystemic shunt, (balloon-occluded retrograde transvenous obliteration), balloon-occluded endoscopic injection sclerotherapy, shunt operation. * hepatic encephalopathy grade iii/iv, * cardio respiratory failure * pregnancy
isoflavones and the coronary circulation in men and women with coronary artery disease

Conditions: Coronary Artery Disease

Summary: the aim of this study is to investigate the effect of genistein administration on coronary arteries in humans. we will measure the size of a coronary artery and the speed and amount of blood flow in response after subjects have ingested supro® drinks (a soy protein drink containing genistein).


Eligibility criteria:
inclusion criteria: * aged 30-75 years * patients requiring diagnostic coronary angiography * presence of coronary artery disease on angiogram but with at least one non-obstructed (lesions \<70% narrowed compared with the adjacent normal part of the vessel) atheromatous vessel (confirmed at diagnostic cardiac catheterisation) * female patients must be postmenopausal (fsh\>40 iu/l) * willing to give informed, written consent exclusion criteria: * age \ 75 years * allergy to radiographic contrast media * sino-atrial disease or significant bradycardia * concomitant medication with persantin (dipyridamole) or theophyllines * asthma * hypertension * left ventricular hypertrophy or dysfunction (clinical/ecg/echo/cxr) * female patients with fsh\<40 iu/l (postmenopausal) * female patients currently taking hormone therapy, or who have taken hormone therapy in previous 6 months * unwilling to give written informed consent * participation in another study within previous 60 days

Keywords: arteries blood flow coronary artery disease diet
efficacy and safety of tmz plus cddp in the patients with recurrent malignant gliomas

Conditions: Malignant Gliomas

Summary: temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant gliomas.cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of tmz. up to now, the prognosis of recurrent gliomas is very pessimistic and the standard treatment procedure has not been established yet. the prospective,multicentre phase ii clinical study is to evaluate the efficacy and safety of tmz and cddp in patients with recurrent malignant gliomas


Eligibility criteria:
inclusion criteria: * written informed consent * age\>=18 and \<=70years old * histological diagnosis of malignant gliomas(who iii or iv) * the status of methylation of promotor of mgmt should be detected. * the time to be enrolled should be more than 90 days after the irradiation. * the patients with recurrent gliomas were treated with non-dose-dense tmz therapy before enrollment. * performance status(karnofsky index)\>=60 * life expectancy more than 3 months exclusion criteria: * ages:\ 70 years * abnormal function of liver or renal(value more than 1.5 fold normal upper limit ) * blood routing: hb \< 100g/l， wbc \< 4.0×109/l; plt \< 100×109/l * pregnant or lactating women * allergic to administered drugs * radiation treatment in the previous 90 days or stereotactic radiation surgery within 60 days before enrollment * the patients with recurrent gliomas were treated with dose-dense tmz therapy before enrollment. * life expectancy less than 3 months * participation in other clinical trials in the 90previous days before enrollment

Keywords: temozolomide(tmz) cisplatin(cddp) recurrent malignant gliomas
tracheal intubation in morbidly obese (bmi>35) and in lean (bmi<30) patients using mcgrath mac x-blade

Conditions: Obesity, Morbid

Summary: 80 lean (bmi\ 35) patients undergoing elective surgery were enrolled in this prospective ransomi̇zed study were intubated using mcgrath mac x-blade. the demographic and airway variables of patients and insertion and intubation times with these dievices, need for optimisation maneuvers, hemodynamic changes and minör postoperative complications were recorded.

80 lean (bmi\ 35) patients undergoing elective surgery were enrolled in this prospective ransomi̇zed study were intubated using mcgrath mac x-blade. the demographic and airway variables of patients were recorded. airway management variables cormack-lehan grades, insertion and intubation times, need for optimization maneuvers ( cricoid pressure, re-inserting, drawback) , hemodynamic changes in heart rate , blood pressure and minor postoperative complications such as sore throat, dysphasia, hoarseness were recorded.

Eligibility criteria:
inclusion criteria: \> 18 age \<65 age * bmı 35 * undergoing elective surgery requiring endotracheal intubation exclusion criteria: -pregnant * \ 65 years of age * bmı\<35 * upper respiratory tract infection past ten days

Keywords: videolaryngoscope airtraq mcgrath mac morbid obesity intubation
oral contraceptives and body mass index

Conditions: Body Weight; Contraceptive Usage

Summary: the main hypothesis for this study is that increased body mass index (bmi) alters oral contraceptive metabolism in a manner which results in decreased effectiveness in obese women.

this study is being conducted to understand how effective oral hormonal birth control (the pill) is for women with high body mass index ("bmi" - the ratio of your height and weight bmi"). previous studies of birth control traditionally do not include women above a certain bmi number, so safety and efficacy is not clearly understood in this population, yet the pill is still widely used in women with high bmi. reproductive-aged, ovulatory women of obese (bmi \>30 kg/m2), will be placed on oral contraceptives for 2 months, then randomized into two intervention arms for an additional 2 months. at several key time points, synthetic steroid pharmacokinetics, gonadotropins (lh, fsh) and ovarian hormone levels (estradiol, progesterone), ovarian follicular activity by ultrasound monitoring, and cervical mucus testing will be monitored.

Eligibility criteria:
inclusion criteria: * age 18-35 * bmi \> 30kg/m2 * proof of a normal breast and pelvic exam within last 9 months * self reported normal menstrual periods (24-35 days) * good general health * in the investigator's opinion, are subject's veins suitable the repeat blood draws dictated by study protocol * single progesterone level during screening visit ≥ 3ng/ml * hematocrit ≥ 36% exclusion criteria: * contradictions to cocs (history of deep vein thrombosis,myocardial infection, uncontrolled hypertension, pulmonary embolus, diabetes with vascular changes, stroke, migraines with neurologic changes, breast cancer, impaired liver function, uncontrolled thyroid disease, hypersensitivity or allergy to birth control) * smoker (must smoke 0 cigarettes) * actively seeking/involved in a weight loss program * currently pregnant/seeking pregnancy in the next 6 months * currently breast-feeding * past or current diagnosis of polycystic ovarian disease * recent use of birth control (depot medroxyprogesterone: 6 months, progestin implants: 6 months, oral contraceptives, patch or ring: 2 months, hormone impregnated iud: 6 months) * currently taking medication that interferes with coc's (rifampin, carbamazepine, st. john's wort)

Keywords: obesity body weight oral contraception efficacy
biomarkers of diabetic retinopathy progression

Conditions: Type 2 Diabetes Mellitus; Mild Nonproliferative Diabetic Retinopathy

Summary: the purpose of this study is to validate a predictive model of diabetic retinopathy progression in patients with diabetes mellitus type 2 patients to clinically significant macular edema (csme) needing treatment either photocoagulation or intravitreal injections (itv) using non-invasive techniques.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * age over 35 years-old * non-proliferative diabetic retinopathy (levels 20 to 35, according the etdrs criteria) * best corrected visual acuity \> 20/25 on the etdrs chart * informed consent exclusion criteria: * previous laser therapy * other retinal vascular disease * glaucoma * recent intraocular surgery (in the last 6 months) * inadequate ocular media and/ or pupil dilatation that do not permit good quality fundus photography (e.g. cataract) * hba1c \> 11 % at the screening * subject that has a condition or that is in a situation which may put him/her at significant risk, may confound the study results or may interfere significantly with his/ her participation in the study.

Keywords: type 2 diabetes mellitus nonproliferative diabetic retinopathy
washington state community expedited partner treatment (ept) trial

Conditions: Gonorrhea; Neisseria Gonorrhoeae; Chlamydia Trachomatis

Summary: the washington state community expedited partner therapy trial is a stepped-wedge community level randomized trial designed to test the hypothesis that a public health program designed to increase the use of expedited partner therapy can decrease the prevalence of chlamydial infection in young women and the incidence of gonorrhea in washington state. the study intervention will be modeled after and intervention previously evaluated in king county wa (golden mr, sex transm dis 2007;598-603). the intervention has two components: 1) promotion of patient delivered partner therapy (pdpt) use by medical providers in accordance with washington state guidelines; and 2) targeted provision of partner services. pdpt use will be promoted through education and by making medication packs for pdpt available statewide. medical providers will refer selected persons with gonorrhea or chlamydial infection for partner services based on defined criteria associated with failure to ensure partners' treatment. the intervention will be instituted in four waves separated by 6-9 months. each wave will include approximately 6 local health jurisdictions. the order in which health jurisdictions initiate the intervention will be randomly assigned. the study's primary endpoint will be the prevalence of chlamydial infection in women age 15-25 tested through clinics participating in the state's infertility prevention project (ipp) and the incidence of gonorrhea among women as determined through public health reporting.


Eligibility criteria:
with reference to the above question about sampling, we will measure pdpt use in a probability sample of persons with std. chlamydial prevalence will be measured in a sentinel population. gonorrhea incidence will be based on public health surveillance. inclusion criteria: * all non-msm with gonorrhea or chlamydial infection will be eligible for the study intervention. exclusion criteria: * msm

Keywords: patient delivered partner therapy expedited partner therapy partner notification gonorrhea chlamydia
lung transplantation for pleuroparenchymal fibroelastosis

Conditions: Fibroelastosis

Summary: this retrospective observational study will evaluate the outcomes of lung transplantation for a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. data will be collected from all transplantation center in france.


Eligibility criteria:
inclusion criteria: * lung transplantation (any type) for pleuroparenchymal fibroelastosis * histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs exclusion criteria: * all other interstitial lung disease than pleuroparenchymal fibroelastosis * pleuroparenchymal fibroelastosis who didn't underwent lung transplantation
topical il-1-ra for treatment of corneal neovascularization

Conditions: Corneal Neovascularization

Summary: the purpose of this study is to determine the effectiveness and safety of interleukin-1-receptor antagonist eye drops for the treatment of corneal blood vessels.

normally avascular, under many pathologic conditions, vessels may invade the cornea from the limbal vascular plexus. infection, inflammation, ischemia, degeneration, or trauma, and the loss of the limbal stem cell barrier can cause corneal neovascularization. growth of new vessels may result in corneal scarring, edema, lipid deposition, and inflammation that may alter visual acuity and is a leading cause of monocular visual impairment and blindness. additionally, it results in the loss of immune response across the cornea, thereby worsening the prognosis of a subsequent penetrating keratoplasty (pk). growth of new blood and lymphatic vessels from preexisting vessels are mediated by members of the vascular endothelial growth factor (vegf) family. this study is designed to investigate whether interleukin-1-receptor antagonist is a drug that is both safe and effective in blocking vegf pathways, stopping new growth, and reducing old vessel growth.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study * age \> 18 years * patients with superficial or deep corneal nv that extends farther than 1 mm from the limbus * patients are in generally good stable overall healthexclusion criteria: • has received treatment with anti-vegf agents (topical, intraocular or systemic) within 30 days of study entry * corneal or ocular surface infection within 30 days prior to study entry• ocular or periocular malignancy * contact lens (excluding bandage contact lens) use within 2 weeks prior to study entry * persistent epithelial defect (\>1mm and ≥14 days duration) within 2 weeks prior to study entry * intravitreal or periocular steroids within 2 weeks prior to study entry * change in dose/frequency of topical steroids and/or nsaids within 2 weeks prior to study entry * pregnancy (positive pregnancy test) or lactation * premenopausal women not using contraception * signs of current infection, including fever and current treatment with antibiotics * participation in another simultaneous medical investigation or trial
a study to evaluate safety and efficacy of ap-306 in hyperphosphatemia patients

Conditions: Chronic Kidney Diseases; Hyperphosphatemia

Summary: the goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus: * how much effect ap-306 has assessed by blood phosphorus lowering; * how safe and tolerable ap-306 is. participants will receive either following treatments: * ap-306, and * sevelamer carbonate.


Eligibility criteria:
important inclusion criteria: 1. on a stable hemodialysis regimen at a frequency of three times per week for at least 12 weeks prior to the screening visit 2. dialysis sufficiency spkt/v ≥ 1.2 at the screening visit or any documented result within 12 weeks prior to the screening visit 3. serum phosphorus within the trial-required range important exclusion criteria: 1. pregnant or breastfeeding 2. any history of kidney transplant 3. any history of a parathyroid intervention 4. any clinically significant gi disorders within 4 weeks prior to the screening visit 5. hospitalization for cardiac or cerebrovascular disease within 24 weeks prior to the screening visit 6. hospitalization for cardiac or cerebrovascular disease within 24 weeks prior to the screening visit 7. documented history of hypersensitivity or allergic reactions to any of the excipients used by ap-306, or history of hypersensitivity or allergic reactions or intolerant to sevelamer carbonate
a prospective multicenter study for the assessment of treatment patterns, effectiveness and safety of secukinumab in adult patients with moderate to severe plaque psoriasis in a real-world setting in china

Conditions: Psoriasis

Summary: this non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in chinese patients with moderate to severe plaque psoriasis (with and without psa) initiating treatment of secukinumab.

all patients will be followed up for 52 weeks no matter they adhere to secukinumab or they have shifted to other treatment plans. data will be collected in conjunction with routine care visits, most likely happen at week 0, 4, 12, 16, 24, 36, 52. no extra study visits, examinations, laboratory tests or procedures will be mandated. if visits happen at other time points (not within the window period), then they will be counted as unscheduled visits.

Eligibility criteria:
inclusion criteria: * aged ≥ 18 years; * diagnosis of clinically moderate to severe plaque-psoriasis; * initiating treatment with secukinumab during the identification period or within 30 days prior to the index date; * patient agrees to sign the informed consent exclusion criteria: - participation in any dermatology or rheumatology clinical trial, concurrent or within the last 30 days of the secukinumab initiating date

Keywords: psoriasis china secukinumab real world study
a prospective, post-marketing registry on the use of chondromimetic for the repair of osteochondral defects

Conditions: Osteochondral Defects

Summary: the objective of this post-marketing study is to confirm the clinical efficacy and safety outcome of treatment with chondromimetic in a patient population within the proposed indication (osteochondral cartilage defects), over a 36 months post-implantation follow-up period. the primary objective is to collect post-marketing safety data in a real life setting by means of (s)adr reporting. the secondary objectives are: * clinical outcome as assessed by patient reported euroqol-5d * structural repair as assessed by mri * the number of treatment failures and the time to treatment failure * the ease of use of chondromimetic as reported by the surgeon


Eligibility criteria:
inclusion criteria: 1. signed patient informed consent 2. shallow osteochondral defect ≤ 12 mm diameter and ≤ 8 mm depth in weight bearing area 3. agree to actively participate in a rehabilitation protocol exclusion criteria: 1. severe vascular or neurological disease 2. uncontrolled diabetes 3. severe degenerative joint disease 4. pregnancy 5. presence of infection at the site or in the joint space (e.g. osteomyelitis) 6. diagnosis rheumatoidism 7. advanced osteoarthritis as judged by the surgeon 8. drug and/or alcohol abuse 9. hypercalcemia 10. known allergy to any of the components of the device (e.g. bovine collagen) 11. bleeding disorders of any etiology 12. steroidal or immunosuppressive maintenance therapy

Keywords: osteochondral regenerative repair cartilage lesion
an open-label, uncontrolled clinical trial of oral 566c80 for the treatment of patients with severe pcp who are intolerant and/or unresponsive to therapy with trimethoprim/sulfamethoxazole and parenteral pentamidine

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: to facilitate provision of atovaquone (566c80) to patients who have severe pneumocystis carinii pneumonia (pcp) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( tmx / smx ); to monitor serious adverse events attributable to 566c80.


Eligibility criteria:
inclusion criteria patients must have the following: * clinical diagnosis of acute severe pneumocystis carinii pneumonia (pcp). * dose-limiting intolerance to tmp / smx and parenteral pentamidine. * willingness and ability to give informed consent. exclusion criteria co-existing condition: excluded: * patients with a history of intolerance to 566c80. patients with the following prior conditions are excluded: history of serious dose-limiting adverse experience during previous 566c80 therapy, thought to be attributable to the drug. required: * trimethoprim / sulfamethoxazole (tmp/smx); pentamidine.

Keywords: trimethoprim-sulfamethoxazole combination pneumonia, pneumocystis carinii pentamidine antifungal agents acquired immunodeficiency syndrome atovaquone
an open trial to assess the tolerability of avanz mite mix immunotherapy

Conditions: Allergic Rhinitis Due to Dust Mite

Summary: the purpose of the trial is to assess the tolerability of the up-dosing phase of avanz mite mix.

the frequency of patients with adverse reactions will be the primary endpoint.

Eligibility criteria:
inclusion criteria: * male and female patients 18-65 years of age. * a clinical history of hdm induced allergic rhinoconjunctivitis with or without asthma at least one year prior to trial entry. * positive spt to dermatophagoides pteronyssinus (der pte) or dermatophagoides farinae (der far) (wheal diameter ≥ 3 mm). * a positive specific ige against der pte or der far (≥class 2; ≥0.70 ku/l) documenting in the last 5 years. exclusion criteria: * fev1 \< 70% of predicted value at screening after adequate pharmacologic treatment. * uncontrolled or severe asthma. * a clinically relevant history of symptomatic perennial allergic rhinitis and/or conjunctivitis caused by an allergen, to which the subject is regularly exposed and sensitized. * history of severe asthma exacerbation or emergency room visit or admission for asthma in the previous 12 months. * at screening, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infection (serous otitis media is not an exclusion criterion). * treatment with parenteral corticosteroids, oral corticosteroids or anti-ige in the previous 3 months or during the study (except for steroids if needed as rescue medication). please, see table 4. * currently treated with angiotensin converting enzyme (ace) inhibitors, tricyclic antidepressants, β-blockers, mono amine oxidase inhibitors (maois) and any other drug containing alum (e.g. antacids) taken on a daily basis. * previous treatment by other allergen concomitant it or immunotherapy with hdm extracts within the previous 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment has been discontinued before reaching maintenance dose; for slit 3 months in the last 5 years is accepted). * history of anaphylactic shock due to e.g. food, insect venom, exercise or drug. * history of severe and recurrent angioedema. * any contraindication according to the investigator brochure (ib). * use of an investigational drug within 30 days prior to screening.

Keywords: house dust mites sensitisation